Carbon Biosciences
Mr. Steinberg is a General Partner at Longwood Fund and Chief Executive Officer and co-founder of Longwood portfolio company Pyxis Oncology. He joins from PureTech Health, (LSE: PRTC), a biotech
incubator which he co-founded and served as Chief Innovation Officer, focusing on venture creation, investing, and launching innovative biotech companies. Mr. Steinberg was the co-founder and CEO of several biotech companies, including Longwood-founded Pyxis Oncology, Vedanta Biosciences, Calix, Vor Biopharma (NASDAQ:VOR) and was co-founder of Restorbio (NASDAQ: TORC). He previously worked in biopharma strategy consulting at Boston Consulting Group and Vertex Partners, and R&D at P&G Pharmaceuticals. He received his MBA in strategy and finance from the University of Chicago Booth School of Business and holds a BA in biology from Cornell University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Carbon Biosciences
1 followers
Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.